Preclinical pharmacology of alogabat: a novel GABAA-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired GABAA signaling

Preclinical pharmacology of alogabat: a novel GABAA-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired GABAA signaling

BackgroundAlterations in the GABAergic system contribute to the pathophysiology of neurodevelopmental disorders, including autism spectrum disorder (ASD) and Angelman syndrome (AS), particularly in cases involving large deletions in the 15q11–13 region. Positive modulation of GABAA-α5 receptors may...

Full description

Saved in:
Bibliographic Details
Main Authors: Giuseppe Cecere, Theresa M. Ballard, Frederic Knoflach, Michael Honer, Joerg F. Hipp, Pilar Garces, Thomas Mueggler, Basil Künnecke, Andreas Bruns, Eric P. Prinssen, Philipp Schoenenberger, Philipp Janz, Roger Redondo, Barbara Biemans, Henner Knust, Andrés Olivares-Morales, Alessandro Brigo, Jan Michael Schulz, Daniel Bertrand, Michael Saxe, Eoin C. O’Connor, Maria-Clemencia Hernandez
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Pharmacology
Subjects:
autism spectrum disorder
Angelman syndrome
GABAA
GABAA-α5
positron emission tomography (PET)
electroencephalography
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1626078/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1626078/full

Similar Items